Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)
China flag China · Delayed Price · Currency is CNY
25.08
-0.61 (-2.37%)
Nov 17, 2026, 3:00 PM CST

SHA:688319 Revenue

Chengdu Olymvax Biopharmaceuticals had revenue of 237.61M CNY in the quarter ending September 30, 2026, with 18.17% growth. This brings the company's total for the last twelve months to 796.18M, up 12.27% year-over-year. In the year 2025, Chengdu Olymvax Biopharmaceuticals had annual revenue of 704.16M with 19.58% growth. That makes Chengdu Olymvax Biopharmaceuticals the 21,402nd largest company in the world by revenue and 3,923rd in China.

Revenue (ttm)
796.18M
Revenue Growth
+12.27%
P/S Ratio
12.77
Revenue / Employee
1.83M
Employees
436
Market Cap
10.17B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2025704.16M115.30M19.58%
Dec 31, 2024588.86M92.74M18.69%
Dec 31, 2023496.12M-51.36M-9.38%
Dec 31, 2022547.48M60.33M12.38%
Dec 31, 2021487.15M167.04M52.18%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.